MDS Proteomics Partners With Abgenix to Identify Protein Targets, Develop Antibodies | GenomeWeb

NEW YORK, June 29 – MDS Proteomics will to identify up to 150 proteins as drug targets in a collaboration with antibody-based pharmaceutical company Abgenix, and in return Abgenix has agreed to make a $15 million equity investment in MDS Proteomics, the companies said Friday.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: convergent evolution in bird hemoglobin, and more.

The Wall Street Journal speaks with patients affected by questionable test results from Theranos.

Researchers link variants in TACR3 to hot flashes during menopause, Live Science reports.

Kuwait says it will alter its law requiring citizens and visitors to provide DNA samples, New Scientist reports.